MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-19-2022
Calliditas Therapeutics AB (publ) Retained Earnings 2011-2025 | CALT
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Calliditas Therapeutics AB (publ)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.43 B | -925 M | -488 M | -456 M | -320 M | -233 M | -176 M | - | - | - | - |
All numbers in SEK currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -176 M | -1.43 B | -575 M |
Quarterly Retained Earnings Calliditas Therapeutics AB (publ)
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -1.82 B | -1.66 B | -1.45 B | - | -1.21 B | -1.05 B | -919 M | - | -613 M | - | -488 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in SEK currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -488 M | -1.82 B | -1.15 B |
Retained Earnings of other stocks in the Drug manufacturers industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Canopy Growth Corporation
CGC
|
-10.9 B | $ 1.68 | -3.44 % | $ 181 M |  Canada |
 |
Alimera Sciences
ALIM
|
-418 M | - | - | $ 142 M |  USA |
 |
Assertio Holdings
ASRT
|
-652 M | $ 0.74 | -3.53 % | $ 52.6 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-1.15 B | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-457 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-305 M | - | 0.86 % | $ 117 M | USA |
 |
Cronos Group
CRON
|
1.06 B | $ 3.05 | -6.88 % | $ 1.61 B | Canada |
 |
Agile Therapeutics
AGRX
|
-423 M | - | 10.11 % | $ 58.2 M | USA |
 |
Aurora Cannabis
ACB
|
-3.59 B | $ 5.1 | -5.59 % | $ 86.3 M | Canada |
 |
Catalent
CTLT
|
-781 M | - | - | $ 11.5 B | USA |
 |
HEXO Corp.
HEXO
|
-659 M | - | 2.45 % | $ 38.1 M | Canada |
 |
DURECT Corporation
DRRX
|
-589 M | - | - | $ 50.1 M | USA |
 |
Organogenesis Holdings
ORGO
|
-40.1 M | $ 4.76 | -1.14 % | $ 627 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
112 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-15.4 B | - | - | $ 28.9 M |  Irlanda |
 |
Pacira BioSciences
PCRX
|
-206 M | $ 26.64 | 1.33 % | $ 1.23 B | USA |
 |
Emergent BioSolutions
EBS
|
-21.8 M | $ 12.27 | 7.44 % | $ 628 M | USA |
 |
Evoke Pharma
EVOK
|
-123 M | $ 10.97 | 0.14 % | $ 36.7 M | USA |
 |
Athenex
ATNX
|
-1.02 B | - | -23.39 % | $ 1.76 M | USA |
 |
Rockwell Medical
RMTI
|
-397 M | $ 0.88 | -5.2 % | $ 20.5 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-794 M | $ 21.43 | 0.3 % | $ 2.04 B |  France |
 |
Sonoma Pharmaceuticals
SNOA
|
-198 M | $ 3.52 | -2.07 % | $ 4.37 M | USA |
 |
Evolus
EOLS
|
-609 M | $ 7.14 | 1.42 % | $ 443 M | USA |
 |
Harrow Health
HROW
|
-134 M | $ 46.39 | -1.43 % | $ 1.51 B | USA |
 |
China Pharma Holdings
CPHI
|
-44 M | $ 1.53 | -1.92 % | $ 26.7 M |  China |
 |
Bausch Health Companies
BHC
|
-9.78 B | $ 6.87 | -0.79 % | $ 2.51 B | Canada |
 |
Veru
VERU
|
-295 M | $ 2.39 | -1.24 % | $ 322 M | USA |
 |
Lannett Company
LCI
|
-596 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
-145 M | $ 1.81 | -5.99 % | $ 402 M | Canada |
 |
cbdMD
YCBD
|
-182 M | $ 1.18 | -3.28 % | $ 5.09 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-24 M | $ 3.04 | 20.16 % | $ 42.7 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-187 M | - | - | $ 193 M | Canada |
 |
Solid Biosciences
SLDB
|
-783 M | $ 5.77 | -1.79 % | $ 236 M | USA |
 |
PetIQ
PETQ
|
-161 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
-561 M | $ 4.34 | 6.9 % | $ 131 M | USA |
 |
Jupiter Wellness
JUPW
|
-115 M | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
-2.25 B | $ 12.77 | -2.85 % | $ 1.75 B | USA |
 |
ProPhase Labs
PRPH
|
11.8 M | $ 0.12 | 0.87 % | $ 1.9 M | USA |
 |
Radius Health
RDUS
|
-1.37 B | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-279 M | - | -4.76 % | $ 65.3 M | USA |
 |
Sundial Growers
SNDL
|
-565 M | $ 1.96 | -11.31 % | $ 3.37 M | Canada |
 |
OptiNose
OPTN
|
-720 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-148 M | - | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
-355 M | $ 0.64 | -0.91 % | $ 30.6 M | USA |
 |
Tricida
TCDA
|
-810 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
-2.42 B | $ 11.19 | -7.9 % | $ 6.92 B | Canada |
 |
TherapeuticsMD
TXMD
|
-950 M | $ 1.7 | -2.86 % | $ 17.7 M | USA |
 |
Zomedica Corp.
ZOM
|
-171 M | - | -0.21 % | $ 98 M | USA |
 |
Viatris
VTRS
|
5.18 B | $ 11.65 | - | $ 14.1 B | USA |